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Uncontrolled hemorrhage is a major preventable cause of death in trauma, the latter accounting for 9% of global deaths. 32 
There is no agreed definition of trauma-induced coagulopathy (TIC), the term is used to describe abnormal coagulation 33 
attributable to trauma. Early TIC occurs within 6 hours of injury and is characterized by hypocoagulability resulting in 34 
bleeding; whereas late TIC represents a hypercoagulable state associated with thromboembolic events and multiple organ 35 
failure. 36 
Research into pathophysiological mechanisms have recognized that acute blood loss, metabolic acidosis, endothelial 37 
activation, immune system of activation, platelet activation, and traumatic brain injury account for the diverse phenotypes 38 
of TIC. Multiple haemostatic abnormalities have been described including fibrinogen depletion, inadequate thrombin 39 
generation, platelet dysfunction, dysregulated fibrinolysis, and endothelial dysfunction resulting in various phenotypes. 40 
Diagnosis is made by detecting abnormalities in viscoelastic haemostatic assays (VHA) or coagulation screening especially 41 
prolonged prothrombin times. 42 
Management priorities are controlling blood loss and reversing shock with balanced ratios of blood products; alongside 43 
prehospital tranexamic acid in long transport or austere environments. There is no international agreement on the 44 
composition of initial blood components for presumed TIC. For those who survive, there are high rates of morbidity 45 
especially in those with traumatic brain injury, which dominates short and long term quality of life and functional outcome. 46 
[H1] Introduction 47 
 48 
Injury is the fourth leading cause of mortality worldwide, accounting for 9% of world’s deaths and claiming 4.9 million 49 
lives worldwide in 20161. Moreover, the burden is higher in individuals younger than 50 years, among whom injury as a 50 
cause of death is second only to infectious diseases. Early preventable deaths (Box 1) after injury in civilian 2 and military 51 
3 settings are primarily attributable to uncontrolled hemorrhage2-8 while later preventable deaths are attributed to 52 
hypercoagulability9. Consequently, there is intense interest worldwide in the pathogenesis of trauma-induced coagulopathy 53 
(TIC) to attenuate its adverse effects on outcome of the seriously injured patient. 54 
Impaired coagulation following sudden death from injury has been appreciated for centuries10.  In the 1960’s the first 55 
clinical laboratory documentation of the temporal changes in coagulation following severe injury were documented11. 56 
However, specific interventions to address these early endogenous changes in coagulation were not specifically addressed 57 
until 1982 when a case series of major abdominal vascular injuries highlighted trauma-induced coagulopathy (TIC) as a 58 
common direct cause of early postinjury mortality, observing that 89% of the deaths were bleeding-related, yet half 59 
occurred after mechanical control of bleeding sites, i.e., due to coagulopathy12. Management of these physiologic 60 
derangements include damage control resuscitation (early blood products, avoiding hemodilution with crystalloids, and 61 
hypotensive resuscitation)13,14 and damage control surgery (temporary packing of bleeding sites until reversal of 62 
TIC)15,16 (Box 1).  However, the remaining ongoing quagmire is the inability to distinguish between patients with 63 
exsanguinating injuries whose TIC is provoked by metabolic failure (“bleeding because they are dying”), from patients 64 
whose TIC is the cause of ongoing blood loss (“dying because they are bleeding”)17. Furthermore, not all patients with 65 
abnormalities in laboratory coagulation tests are bleeding 18. 66 
Despite the long-term fascination with changes in coagulation resulting from shock and tissue injury19191919191818181919, there 67 
is no standard definition of TIC. TIC refers to abnormal coagulation capacity attributable to trauma. TIC can manifest in a 68 
spectrum from hypo- to hyper-coagulation (Figure 1), as a function of several interactive factors, including (but not limited 69 
to): tissue injury, presence of shock and, especially, time from injury (Figure 2). For discussion purposes, we suggest the 70 
terms early and late TIC, but acknowledge that the phenotypes can vary substantially within these time periods. Early TIC 71 
(generally within 6 hours of injury) is characterized by the inability to achieve hemostasis, which may lead to uncontrolled 72 
hemorrhage and protracted shock; whereas late TIC (usually >24 hours postinjury) is represented by a hypercoagulable 73 
state, which may result in excessive macro- and micro-clotting leading to thromboembolic events (e.g., deep venous 74 
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thrombosis and pulmonary embolism) or to acute respiratory distress syndrome (ARDS) and multiple organ failure (MOF). 75 
Early and late TIC are not mutually exclusive, i.e., patients may develop early TIC due to massive blood loss but succumb 76 
to extensive microvascular occlusion recognized as irreversible shock. Furthermore, the transition from hypocoagulability 77 
to hypercoagulability may occur within minutes / hours or delayed for days. The National Institutes of Health (NIH) 78 
conducted a Trans-Agency Coagulopathy in Trauma Workshop in April 2010. Out of this meeting came the consensus for 79 
the term “trauma-induced coagulopathy” (TIC) to describe these phenomena.  80 
Despite the lack of a clear definition of TIC, there appears to be agreement on a related but distinct syndrome, disseminated 81 
intravascular coagulation (DIC). DIC is defined as "an acquired syndrome characterized by the intravascular activation of 82 
coagulation with a loss of localization arising from different causes"20. Recently, a consensus statement from the 83 
International Society of Thrombosis and Hemostasis (ISTH) clarified the common as well as distinct mechanisms of DIC 84 
versus TIC21. Early TIC is dominated by acute blood loss with associated shock (ischemia/reperfusion), impaired clot 85 
formation and, in advanced cases, hyperfibrinolysis (Figure 1). Following trauma, tissue factor (TF) facilitates clot 86 
formation at sites of endothelial injury; whereas, in DIC there is unbridled systemic clotting promoted by TF expression on 87 
a number of cell surfaces. Ultimately, late systemic prothrombotic/antifibrinolytic TIC mirrors certain DIC phenotypes22. 88 
In this Primer, we will describe what is known of TIC, but perhaps more importantly will acknowledge what remains to be 89 
defined (Box 2). Our primary objective is to provide a broad picture of the entity TIC to inspire investigators from diverse 90 
disciplines to pursue answers to the substantial gaps in knowledge. 91 
[H1] Epidemiology     92 
   93 
Uncontrolled bleeding causes 25% of all injury-related deaths 23-31, and 40-80 % of potentially preventable deaths 32, (Box 94 
1) both in military and in civilian settings (Table S1). At least a quarter of these are likely to have a  TIC component33. The 95 
phenomenon is observed globally: Australian29 and Canadian34 studies implicated hemorrhage in 15-33% of injury deaths. 96 
In Stavanger, Norway, 25% of the 1996-2004 trauma deaths were due to exsanguination.30 In a Turkish hospital, from 2010-97 
2013, circulatory collapse accounted for 33% of injury mortality.35 In Brazil, hemorrhage claimed 18% of the trauma deaths 98 
in an urban hospital.36 Although two European studies37,38 exhibited lower proportions of hemorrhagic deaths, these studies 99 
classified polytrauma, chest injury, and cardiac arrest as separate, non-hemorrhagic causes of death. Differences in 100 
populations, injury mechanisms as well as healthcare resources explain the disparities in statistics. Since the 1990’s when 101 
bleeding caused over one third of trauma fatalities24,, we have made little progress as hemorrhage  accounts for 20-34% of 102 
current trauma mortality.28,39 While a US urban trauma center observed a reduction in bleeding deaths after implementing a 103 
bleeding-control bundle-of-care (from 36% to 25%)31, (Box 1) hemorrhage remained frequent among potentially 104 
preventable deaths (48% vs. 43%)40.  105 
Understanding the timing of hemorrhagic deaths is crucial to determine when hemostatic therapies are most effective, and 106 
which outcomes (i.e., massive transfusion, all-cause vs hemorrhagic deaths, early vs late mortality) they may affect 4,41. 107 
Trauma deaths immediately postinjury are often due to irreparable injuries, thus hemostatic interventions are likely to impact 108 
hemorrhagic deaths over the ensuing hours. Randomized controlled trials (RCT)2,5,6,14,42-44 and observational studies34,35,45 109 
unequivocally show that hemorrhagic deaths occur within 24 hours, mostly within 3-6 hours. TBI competes as a dominant 110 
cause of death in the 6-24-hour period and multiple organ failure (MOF) predominates after the first week2. In the CRASH-111 
2 trial, representing primarily developing countries, 34% of all deaths were attributed to bleeding, 50% within 10 hours.43  112 
Analyses of three recent US randomized controlled trials focusing on postinjury hemorrhage control, with relatively similar 113 
populations, methods, and healthcare resources, most hemorrhagic deaths occurred in the first 6 hours (Figure 3). 7,46 Half 114 
of all deaths in the first 3-6 hours in these three RCTs were due to hemorrhage. 115 
The incidence of TIC diagnosed via laboratory tests varies widely (Table S2) but most studies converged around a TIC 116 
incidence of 25% of severely injured patients, with an associated 35-50% mortality. Tissue injury severity and shock/ 117 
hypoperfusion are the major risk factors (Table S2). Civilian47 and military48 studies indicate that TIC is accentuated when 118 
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both exist. Metabolic acidosis and penetrating mechanism are commonly reported TIC risk factors (Table S2).  Very young 119 
children develop TIC more frequently than older children, and children in general develop TIC later and less frequently 120 
than adults49. The elderly are more vulnerable to TIC than younger adults50,51. Longer prehospital times52 and prehospital 121 
crystalloids52,53 worsen TIC. TIC’s magnitude correlates with traumatic brain injury (TBI)’s severity (Table S2), but 122 
studies54,55 suggest that hypoperfusion is an important cofactor. An often-neglected factor is hypocalcemia, caused both by 123 
shock and citrated blood products (especially plasma and platelets), and it has been suggested that the “lethal triad” should 124 
include hypocalcemia and become the “lethal diamond”56,57. On the other hand, it is important to recognize that while TIC 125 
is common in the severely injured, many patients with laboratory-based TIC do not have substantial bleeding18. 126 
 127 
[H1] Mechanisms/pathophysiology 128 
  129 
[H2] Hemorrhagic Shock   130 
The pathophysiology of hemorrhagic shock is fundamentally blood volume depletion with diminished oxygen delivery to 131 
the microcirculation, ultimately resulting in metabolic acidosis. Although isolated transient hemorrhagic shock may be 132 
tolerated, compounded by tissue injury, hemodilution, and acidosis it is a major driver of TIC.  It is important to distinguish 133 
early, hypocoagulable TIC (Figure 2) from iatrogenic coagulopathy due to resuscitation with large volumes of cold fluids 134 
and blood products, which leads to: 1) dilution of enzymes required for clot formation, and 2) hypothermia, which impairs 135 
clotting factor activity and platelet function12,58. The hypocoagulable TIC phenotype can be attributed partially to metabolic 136 
acidosis due to reduced blood perfusion of tissue beds and organs52,59-63. In animal studies and in vitro experiments, acidosis 137 
has been shown to retard polymerization and clot strengthening in viscoelastic tests60, (Box 1) decrease factors V and IX 138 
activity and platelet aggregation64, increase fibrinogen consumption61, reduce platelet count, thrombin generation, and 139 
maximum clot strength, and induce abnormal conventional coagulation tests59. A pH drop from 7.4 to 7.2 reduces the activity 140 
of each of the coagulation proteases by more than half 63,65. A swine model showed that acidemia (pH 7.1) was associated 141 
with depleted plasma fibrinogen by 34%, platelet count by 51%, and thrombin generation in the propagation phase by nearly 142 
50%. Hypothermia is now less frequent with modern hemostatic, goal-directed resuscitation (Box 1) with warm fluids 143 
66,67, but it should not be overlooked. Wolberg and colleagues 68 in an in-vitro study of healthy volunteer blood, noted a 144 
significant reduction in both platelet function and coagulation enzyme activity at temperatures <33 °C. Hypothermia remains 145 
a marker for poor prognosis after hemorrhage, probably representing metabolic dysfunction52,69-71 Shock also leads to auto-146 
dilution, (Box 1) i.e., shifts of interstitial fluid into the vascular compartment, which may impair hemostatic capacity72. 147 
Activation of protein C (aPC) may be a contributing mechanism 33,54,55,73. Trauma-induced hypoperfusion has been reported 148 
to activate PC, which may inactivate factors V and VIII, and is associated with reduced plasminogen activator inhibitor-1 149 
(PAI-1). Elevated aPC predicts adverse postinjury outcomes, however, the mechanistic role of aPC in TIC has been disputed. 150 
Specifically, platelets and plasma Factor Va are resistant to aPC cleavage at concentrations of aPC seen in TIC72. While 151 
hypothesized that aPC binds to PAI-1 and thus de-represses t-PA, it seems more likely that the enormous  release of t-PA 152 
from endothelium is due to epinephrine, vasopressin, and thrombin signaling as well as hypoperfusion, which drives the 153 
fibrinolytic phenotype of TIC74.  154 
In addition, metabolic byproducts, such as succinate, have been associated with early TIC75, and oxidative stress has been 155 
shown to modify fibrinogen polymerization resulting in weaker clots76. Finally, hypocalcemia is another mechanism by 156 
which hemorrhagic shock can impair coagulation. Calcium plays an important role in the formation and stabilization of 157 
fibrin polymerization sites and, consequently, it has an impact on all platelet-dependent functions77. Yet laboratory 158 
coagulation tests may mask the negative impact of hypocalcemia on coagulation, as blood samples are re-calcified prior to 159 
being assayed. Hypocalcemia is prevalent post-hemorrhage 53, due to resuscitation with citrated blood products, and low 160 
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hepatic clearance of citrate due to defective hepatic perfusion78, as well as other still poorly understood shock-related 161 
mechanisms56,67.  162 
With the progression of the shock state, hypercoagulability ensues due to prothrombotic changes and fibrinolysis shutdown 163 
promoting organ damage by generating thrombi and occluding the microvascular circulation, leading ultimately to organ 164 
failure9,79. Hypocoagulability and increased fibrinolysis during shock may well represent intrinsic mechanisms to prevent 165 
these events from occurring; it remains debatable whether these are adaptive or pathologic responses80.  166 
[H2] Tissue Injury  167 
Tissue damage with endothelial disruption activate the coagulation system at the injury site via expression of TF, a 168 
transmembrane protein expressed within the subendothelium that becomes exposed. TF complexes to FVIIa and activates 169 
the coagulation system resulting in thrombin generation and fibrin formation81. Moreover, tissue trauma provokes the release 170 
of damage associated molecular patterns (DAMPs), which stimulate inflammatory pathways by the release of a number of 171 
mediators. Haemostasis and inflammation are interrelated processes that robustly influence one another.  172 
TIC’s development is typically associated with the severity and extent of tissue injury48,82-84. Tissue damage and shock-173 
related hypoperfusion occur together frequently; however, their synergistic contribution to TIC remains unclear.  Multiple 174 
potential pathways have been suggested, including an early effect of DAMPs on platelet function, rendering them 175 
hyporesponsive80,85. Furthermore, an initial thrombin surge would activate endogenous anticoagulation pathways, and some 176 
component of clotting factor consumption may occur in TIC, distinct in mechanism from DIC21. It is also possible that the 177 
pattern of tissue damage contributes to TIC. For example, TBI creates a hypocoagulable state as the cerebral tissue contains 178 
potent procoagulant molecules such as phospholipids, which deplete clotting factors, and provoke platelet inhibitors86. 179 
Damage of organs with high content of tissue plasminogen factor (tPA), such as the pancreas, lung and urogenital system, 180 
may also compromise haemostasis via fibrinolytic activation. However, the exact contribution of these organ injuries are 181 
unknown. It is similarly unclear whether any pre-existing chronic conditions in those tPA-rich organs may modulate TIC 182 
dynamics. Adding complexity, tissue injury has also been directly correlated with fibrinolysis shutdown through release of 183 
cellular by-products of injury, as well as mechanical trauma to red blood cells and platelets releasing their contents87. A 184 
recent study suggested that myosin can bind factors Xa and Va, consistent with their ability to create prothrombinase that 185 
promotes thrombin activation88. Tissue injury has been shown in both pre-clinical models and patient studies to result in the 186 
production of extracellular vesicles from multiple cellular sources, which are strongly prothrombotic and may result in 187 
coagulation factor depletion after injury 89,90.  188 
 [H2] Endothelial Dysfunction    189 
The endothelial cell surface network governs coagulation, inflammation, micro-circulation, and barrier function critical to 190 
vascular homeostasis and oxygen delivery (Figure 4). TIC’s damage to this network, termed the endotheliopathy of trauma 191 
(EOT), is characterized by loss of barrier function, leukocyte adhesion, endothelial activation, and clinical expression of 192 
coagulopathy, micro- and macro-thrombosis, and organ dysfunction, and is likely mechanistically circular, in which TIC 193 
contributes to EOT and vice-versa91. The role of the contact activation system as a result of collagen exposure remains 194 
unclear92. The contact activation system includes the plasma proteins FXII, prekallikrein, and high molecular weight 195 
kininogen (HK). FXIIa cleavage of prekallikrein results in the serine protease kallikrein, which can cleave HK to generate 196 
bradykinin. Bradykinin can induce both the expression of tissue factor (procoagulant) as well tPA (profibrinolytic).  197 
EOT is mediated by hypoperfusion and is characterized by circulating markers of shed endothelial glycocalyx associated 198 
with coagulopathy, inflammatory complications, vascular thrombosis, organ failure, and death (Figure 4)93-95. The 199 
glycosaminoglycan syndecan-1 is the most well-characterized sheddase in TIC91, as its heparan sulfate domain is shed with 200 
hemorrhage and hypoperfusion, catecholamine surges, and oxidative stress. It remains controversial whether auto-201 
heparinization from the heparan sulfate domain contributes to impaired clot formation, as it is variably identifiable by 202 
viscoelastic assays96. Pathologic cleavage of the syndecan-1 ectodomain may be mediated by MMPs of the A Disintegrin 203 
and Metalloproteinase (ADAM) family. However, whether poor outcomes associated with shed proteoglycans are direct or 204 
downstream to altered protective glycoproteins is unclear. Experimental work suggests that tissue injury- and the shock-205 
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driven thrombin-thrombomodulin system activation, and ultimate depletion of protein C, diminish endogenous 206 
cytoprotective effects to the endothelium54,73,97. Additionally, altered platelet-endothelial regulation in TIC may disrupt an 207 
important symbiosis, as soluble CD40, a primarily platelet-derived ligand of endothelial inflammatory cascades, is 208 
associated with TIC98. Further, both sustained exocytosis of structurally ultra-large von-Willebrand factor (vWF) and 209 
impaired MMP ADAMTS13 clearance of vWF are identified in injured patients with TIC 99, and are associated with 210 
prothrombotic and proinflammatory biology99,100, highlighting the importance of endothelial biology in mediation of micro- 211 
and macro-thrombosis (Figure 4). 212 
Animal studies show that endothelial barrier function is restored with plasma 91,101-104, and early plasma of injured patients 213 
is associated with reduced circulating syndecan-1105, providing mechanistic insights for improved outcomes 5,6. ADAM 214 
MMP cleavage of syndecan-1 ectodomains may be mitigated with plasma treatment via Tissue Inhibitor of 215 
Metalloproteinase (TIMP) inhibition or decreased activation of ADAM MMPs. Additionally, newer hypotheses around 216 
mechanisms of tranexamic acid in injured patients center on abrogation of the EOT through serine protease inhibition, 217 
DAMP mitochondrial DNA release suppression, mitochondrial respiration stimulation, and oxidative phosphorylation 218 
enhancement106,107. It remains unknown whether the EOT is cause or effect in TIC, but identification of therapeutic targets 219 
for recovery of endothelial cell surface networks, including characterization of soluble reparative molecules in plasma, 220 
continues to be investigated. 221 
 222 
[H2] Cell-based Model of Hemostasis   223 
The key concept underlying “cell-mediated hemostasis” is that cells play active roles in regulating and localizing the 224 
coagulation reactions 108. Receptors, lipids and other features of cell surfaces are critical to defining the roles of specific cell 225 
types in hemostasis. Many cells participate in hemostasis, but platelets and endothelial cells are the two critical players. 226 
Platelets adhere at a site of injury and provide the surface on which procoagulant reactions occur, as well as controlling the 227 
rate and localization of thrombin production. Normally endothelial cells are actively antithrombotic, thus preventing 228 
propagation of clotting from a site of injury throughout the vasculature. A failure of cell-mediated regulation can lead to 229 
failures of normal hemostasis, even when the protein components are within normal ranges. This concept is particularly 230 
relevant to understanding the mechanisms of bleeding and thrombosis induced by trauma.  231 
In the cell-based model, the process of hemostasis consists of the overlapping events of initiation (extrinsic pathway on TF‐232 
bearing cells), amplification (positive feedback of thrombin on platelets) and propagation of large-scale thrombin generation 233 
(intrinsic pathway on activated platelets) that are regulated by cell surfaces rather than the protein components alone (Figure 234 
5). 235 
The biochemical reactions of physiologic hemostasis are subject to several control levels. Some are reflected in the 236 
“coagulation cascade” that is focused on the roles of the various procoagulant factors (Figure 6). However, additional 237 
regulation levels involve the anticoagulants and protease inhibitors, as well as the cellular and tissue localization of 238 
coagulation. These control mechanisms are barriers to the activation and spread of coagulation, and thereby prevent clot 239 
formation at inappropriate times and places. Physiologic coagulation (hemostasis) is terminated when the area of injury is 240 
surrounded by a platelet/fibrin clot that stops bleeding, forms a physical barrier to the diffusion of activated factors and a 241 
provisional scaffold for healing to occur.  242 
Coagulopathy occurs not only when procoagulants are consumed or diluted, but also when one or more of the control 243 
mechanisms is disrupted. Thus, not only the amount of thrombin generation can be abnormal, but its localization can be 244 
abnormal as well. Because trauma is such a heterogeneous event, it is difficult to define a dominant mechanism of 245 
coagulopathy in trauma. Furthermore, hemostatic function changes over time as bleeding continues, compensatory 246 
mechanisms are engaged and inflammation progresses. 247 
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[H2] Platelet Dysfunction    248 
Despite being subcellular in size and anucleate in structure, platelets are biologically dynamic in coordination of hemostasis, 249 
endothelial health, and immune function109-111. Interest in the platelet role in TIC intensified following the description of the 250 
above-mentioned cell-based model of hemostasis in 2001108. Subsequent accumulating evidence has supported the presence 251 
of quantitative and qualitative112 deficits in primary hemostatic and secondary endothelial and immune-regulatory platelet 252 
functions113,114, in human and animal TIC models, and implicated platelets in the pathogenesis of postinjury venous 253 
thromboembolism (VTE) and multiple organ failure (MOF). 254 
Platelets are central in structure and function to primary procoagulant protein assembly, thrombin generation, fibrin 255 
crosslinking, and fibrinolytic regulation, and secondary endothelial and immune regulation (Figure 4). Failures of both 256 
primary and secondary platelet functions are characteristic of TIC, and can be identified in up to 50% of injured patients, 257 
regardless of severity of injury or presence of shock112. Quantitative consumptive and dilutional thrombocytopenia are 258 
independently associated with bleeding115,116. However, most patients with TIC have preserved platelet counts, evidence of 259 
circulating populations of activated platelets, yet paradoxically impaired ex-vivo aggregation responses117,118. 260 
Phenomenologically, some describe this as “platelet exhaustion”, due to injury and shock119 driven by endothelial release 261 
of TF, platelet activating factor, and vWF100,120, activating platelets beyond what is needed for primary hemostasis at the 262 
local sites of injury, creating circulating platelets that are expended following release of their pro and anticoagulant factors. 263 
It is hypothesized that these circulating expended platelets cannot contribute to primary hemostasis, nor ex vivo aggregation 264 
assays that require platelets to respond to stimulation112,119.  Injured patients with impaired platelet aggregation responses 265 
also exhibit increased sensitivity to tPA mediated fibrinolysis, perhaps due to impaired platelet PAI-1 release121. 266 
Importantly, these acquired platelet dysfunctions of TIC may not be reversed by room temperature platelet transfusions122,123, 267 
which may be due to injury and shock induced circulating platelet inhibitors124.  Cold-stored platelets may be more effective 268 
in restoring platelet contribution to hemostasis.125,126 269 
Efforts for deeper molecular phenotyping90,127-130 have uncovered multiple molecular phenotypes of platelet dysfunction 270 
characteristic of TIC, both adaptive and maladaptive in nature (Figure 4). Beyond the primary effects of platelets 271 
contributing to early TIC and hemorrhage, TIC associated immuneregulation of platelets likely contributes to later TIC 272 
hypercoagulability 114,131. Specifically, injury induced platelet activation stimulates platelet and leukocyte ligand binding 273 
inducing circulating platelet-leukocyte aggregates (PLA), associated with production of procoagulant milieus through the 274 
release of platelet factor-4, and increased expression of TF, fibrinogen, and factor Xa in animal models. Further, platelet-275 
mediated toll like receptor-4 (TLR-4) signaling, histone H4 decoration of platelet procoagulant ballooning, and platelet-276 
derived high mobility group box-1 (HMGB-1) recruitment of monocytes and neutrophil extracellular trap formation90,132,133 277 
are all proinflammatory mechanisms identified in association with early failures in platelet hemostasis and later 278 
hypercoagulability. 279 
Whether the diverse qualitative changes in platelet behavior characteristic of TIC are amicus or adversary remains unclear80, 280 
begging for platelet biomarker, microfluidics, cell-culture, mitochondrial, ultra-structure microscopy, and genomic methods 281 
to uncover platelet targets for alternative TIC therapies beyond human-donated blood products90,100,127,134,135.  282 
 283 
[H2] Inappropriate Thrombin Generation  284 
In initial phases of bleeding, thrombin generation (TG) appears to be insufficient, while later it may contribute to adverse 285 
thrombotic events. The final thrombin concentration is essential for the structure of the developing fibrin clot. Impaired 286 
thrombin concentration results in clots composed of thick fibrin fibres with diminished stability, which are prone to 287 
fibrinolysis. Thus, the balance between TG and inhibition is critical to hemostatic capacity. Depletion of endogenous 288 
inhibitors after injury can offset a decrease in procoagulants and increase risk for thromboembolic complications. 136,137  289 
TG can be altered by dilution of coagulation factors following fluid therapy, rapid coagulation factor consumption 290 
immediately post-injury, shock related systemic acidosis and hypothermia.65,138-140 Severely injured patients are prone to an 291 
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early reduced Factor V 5,141,142 and Factor VII levels 142, and low Factor X142 and fibrinogen concentration 140,142. However, 292 
the reports of decrease in the activity of coagulation factors following severe injury are inconsistent. Concentration of 293 
coagulation factors >30% of normal are generally accepted as sufficient for effective hemostasis143, although this threshold 294 
is based on work with single factor depletion. Data from the prehospital COMBAT study revealed that coagulation factors 295 
activity in severely wounded patients were all over 64% upon hospital arrival.5  296 
Importantly, a reduction in procoagulants is not necessarily accompanied by impaired TG142,144. Even though multiple 297 
procoagulants were found to be lower in trauma patients, TG circulating markers (including prothrombin fragment1-2 and 298 
thrombin-antithrombin complexes) were higher compared to uninjured subjects or patients without evidence of TIC142. 299 
Elevation of these markers reflects formation of thrombi in needing sites and may constitute a physiologic response to 300 
injury, with increased TG in vivo leading to both pro-and anti-coagulant depletion201. Importantly, standard coagulation 301 
assays do not reflect the activity of the anticoagulant systems. Thus, a slightly prolonged assay could reflect a modest 302 
depletion of procoagulants, which is not necessarily accompanied by diminished TG and a bleeding tendency in vivo, given 303 
that it is offset by depletion of anticoagulants 144,145. Blood samples from trauma patients displayed a higher peak “native” 304 
plasma (no activator added) thrombin concentration than healthy individuals despite prolonged standard coagulation tests144. 305 
Recent data indicated that upon hospital admission, trauma patients exhibited 2.5-fold higher average plasma TG compared 306 
to uninjured subjects146. However, low TG capacity was evident in 17% of those patients. Notably, a peak TG <250nM was 307 
linked to 4-fold increased odds for massive transfusion requirement, and 3-fold greater odds of 30-day mortality146.  308 
Furthermore, there may be significant differences between plasma and whole blood thrombin assays 200. Recent data with 309 
whole blood TG data indicate patients who required a massive transfusion had TG below normal controls 20  With respect 310 
to late TIC, thrombin is at the cross-road of coagulation and inflammation (Figure 7), and excessive thrombin generation 311 
may have an important role in delayed hypercoagulability in the injured patient. 137 312 
[H2] Fibrinogen Depletion    313 
Fibrinogen is the most abundant coagulation factor in blood, with circulating levels in the range of 2-4g/L in a healthy adult, 314 
and a circulating half-life of approximately 4 days. Conversion of fibrinogen to fibrin occurs via thrombin-mediated 315 
cleavage at two sites (Figure 8), exposing binding sites for other fibrin molecules, thereby giving rise to spontaneous 316 
polymerization. Each fibrin fiber is comprised of several hundred to several thousand protofibrils aligned side by side, 317 
therefore providing extraordinary strength and resilience to the scaffold protein77. Fibrin fibers are cross-linked by the 318 
transglutaminase enzyme, activated factor XIII, providing additional mechanical strength and resilience to the fibrinolytic 319 
degradation147. In addition, fibrinogen binds with high affinity to integrin αIIbβ3 (also termed glycoprotein IIb/IIIa) on 320 
platelets, thereby facilitating further platelet aggregation, and generating force to contract the fibrin matrix and stabilize the 321 
forming clot.  322 
Fibrinogen is synthesised by hepatocytes, with approximately 98% of circulating human fibrinogen being derived from the 323 
liver148. Circulating fibrinogen levels increase up to 20-fold in the acute phase response, mediated by IL-6 release following 324 
tissue injury, infection and inflammation149. Intriguingly, despite its high circulating concentration, fibrinogen is the first 325 
coagulation factor to reach critically low levels in severe bleeding events150,151. In major trauma, key contributors to 326 
hypofibrinogenemia include hemodilution (due to fluid resuscitation), blood loss, consumption in clot formation at the 327 
wound sites, hypothermia (which impairs fibrinogen synthesis), fibrinogenolysis and increased degradation due to 328 
acidosis139,151. Trauma and hemorrhagic shock are associated with a hyperfibrinolytic state, occurring in the first few minutes 329 
and sometimes persisting for hours following injury152.  These observations are linked to excessive release of tPA from the 330 
endothelium, which swamps availability of its natural inhibitor PAI-1153, thereby driving activation of circulating 331 
plasminogen to plasmin. Increased plasmin generation shifts the balance of the fibrinolytic system, promoting premature 332 
breakdown of fibrin in clots, and also fibrinogen degradation.  333 
Low fibrinogen levels upon admission are independently associated with an increase in injury severity and shock154. 334 
Moreover, the fibrinogen level upon admission is an independent predictor of transfusion, 24-hour and 28-day mortality154-335 
156. Fibrinogen level has been identified as the most important independent predictor of mortality, but whether this value 336 
9 
 
represents a biomarker (as opposed to mediator) in trauma patients remains to be determined.  Current guidelines 337 
recommend fibrinogen supplementation in patients with traumatic bleeding when fibrinogen concentration is <1.5g/L157.  338 
 [H2] Dysregulated Fibrinolysis    339 
Fibrinolysis activation following severe injury has been documented for over half a century11. While the exact 340 
pathophysiology remains unclear, hemorrhagic shock is common in patients who present to the hospital with elevated 341 
fibrinolytic activity 9,158-161. Hyperfibrinolysis is associated with elevated levels of tPA153,162. The source of tPA release 342 
during hemorrhagic shock is presumed to be Weibel-Palade vesicles in the endothelium released in response to multiple 343 
stimuli163.  Weibel-Palade vesicles also store the adhesive protein vWF164, and circulating levels of these factors are 344 
increased following trauma 165. 345 
Hyperfibrinolysis is exacerbated by loss of fibrinolytic inhibitors153,162,165, including alpha-2 anti-plasmin166and platelet 346 
dysfunction167 (Figure 2). Elevated tPA activity with PAI-1 depletion is the hallmark of trauma patients with 347 
hyperfibrinolysis55,153,162,168.  In addition, depletion of secondary tPA inhibitors (C1 inhibitor and α1antitrypsin), or factors 348 
that modulate inhibitor function, such as vitronectin, the cofactor for PAI-1also occurs161.   Platelet alpha granules are the 349 
primary circulating source of PAI-1, which is secreted following stimulation and retained on the surface of activated 350 
platelets169. PAI-1 can also be generated in a number of cells, including endothelium. Additional factors that govern clot 351 
dissolution, including thrombin activatable fibrinolysis inhibitor (TAFI; alternatively named carboxypeptidase U; CPB2) 352 
and factor XIII are depleted in hyperfibrinolytic trauma patients (Figure 9).   The antifibrinolytic function of factor XIII is 353 
conferred by cross-linking of the plasmin inhibitor, α2antiplasmin, into the forming fibrin matrix170. It has been shown that 354 
depletion of factor XIII levels to approximately 50% has a negative impact on clot stability171. This is important, as factor 355 
XIII circulates in complex with fibrinogen, which is also depleted in trauma154,156.  356 
Hyperfibrinolysis is suppressed in most trauma patients by a surge of PAI-1 that initiates at 2 hours from injury and results 357 
in the majority of patients shutdown fibrinolysis activity by 12 hours172. This concept, termed fibrinolysis shutdown173, is 358 
evident in a broad range of diseases, including viral infections such as COVID-19174. While PAI-1 upregulation hours after 359 
injury appears to be a physiologic event, fibrinolysis shutdown that occurs within an hour of severe injury is associated with 360 
2 to 6-fold increased mortality175. These patients exhibit hallmarks of prior fibrinolysis activation, including elevated D-361 
Dimer and depletion of fibrinolytic inhibitors, yet have low systemic fibrinolytic activity on presentation to the emergency 362 
department 161. The precise mechanism of acute fibrinolysis shutdown remains unclear. There is some evidence that the 363 
plasminogen binding protein, S100-A10, is shed into the circulation, and may associate with tPA, thereby impeding 364 
fibrinolysis176. Resuscitation promotes PAI-1 elevation in most injured patients, and the increase is pathologic if sustained 365 
beyond 24 hours172.  366 
Prior fibrinolytic activation with subsequent shutdown is associated with ongoing coagulation abnormalities, including 367 
platelet dysfunction and prolonged prothrombin time176,177. It remains controversial whether these patients may have 368 
shutdown fibrinolysis at the systemic level while having ongoing bleeding at the local tissue level, a phenomenon labeled 369 
as “occult” hyperfibrinolysis176. Regardless of terms, patients with low fibrinolytic activity, measured by viscoelastic 370 
activity and elevated D-Dimer or PAP levels, have increased mortality compared to patients with balanced fibrinolytic 371 
activity, with significantly less blood product utilization compared to patients with hyperfibrinolysis161,176,177. Patients in 372 
fibrinolysis shutdown tend to have delayed mortality from brain injury and organ failure, while hyperfibrinolytic patients 373 
die early from hemorrhage9. To add complexity, a subset of trauma patients do not generate a robust fibrinolytic response, 374 
and present to the hospital in a low fibrinolytic state, which is also associated with increased mortality165. Hypofibrinolysis, 375 
defined as lack of fibrinolysis activation with low fibrinolytic activity remains poorly described in trauma, but may 376 
contribute to thrombotic complications.  377 
Ongoing work on fibrinolysis in trauma has focused on the temporal changes of fibrinolysis following injury. Most  trauma 378 
patients transition to a depressed fibrinolytic state following severe injury178. Trauma patients who retain low fibrinolytic 379 
activity beyond 24 hours (both adults172,178,179 and children180) exhibit increased mortality. This could be attributed to 380 
elevated PAI-1, which is associated with poor outcomes in sepsis, but requires further investigation in trauma. Alternative 381 
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mechanisms to inhibit fibrinolysis include activation of a persistent inflammatory state, in which neutrophil elastase has 382 
been demonstrated to reduce fibrinolytic activity181.  383 
[H2] Sex Dimorphism   384 
Sex dimorphisms in coagulation have been described in humans, with females manifesting a more hypercoagulable 385 
profile182. As females often have less severe, and less penetrating trauma, both important TIC risk factors, isolating the 386 
independent role of sex in TIC is difficult (Tables 1S and 2S).  387 
Sex’s effect on postinjury morbidity and mortality has been somewhat controversial183-186. George et al.187 showed that until 388 
age 50 years, men with blunt injuries had an increased death risk compared to women; among those age 50 years or older, 389 
no survival differential was noted in blunt trauma, but women with penetrating injuries had an increased mortality compared 390 
to men. Other studies across the world showed that premenopausal women have a survival advantage over men183,188,189. 391 
The presence of TIC seems to change this picture as a multicenter trauma study185 found increased mortality among women 392 
presenting with TIC, independent of age.  393 
On TIC’s hypercoagulable side, we also observe disparities between women and men. Although men have higher VTE rates 394 
in their lifetime190,191, women are at higher VTE risk during pregnancy, when using sex hormones and after ovarian 395 
stimulation. In trauma, there is controversy, with some studies showing no sex differences192,193 in VTE rates, while others 396 
reported a higher risk in men191. Interestingly, the latter study accounted for post-discharge VTEs, which represented 62% 397 
of the events.  398 
In studies with native-thrombelastography (TEG), healthy women showed faster clot initiation and stronger clots compared 399 
to men182,194. These differences were more pronounced in pregnant women compared to their non-pregnant counterparts182, 400 
further suggesting that female sex hormones are involved in this protective mechanism. The Denver group195, using rapid-401 
TEG (with TF activation), showed that injured women had faster clot formation and strength, as well as less fibrinolysis 402 
than men, after adjustment for risk factors. Moreover, women were less likely than men to die when presenting with 403 
abnormal maximum amplitude or hyperfibrinolysis, despite being older, having longer time from injury to admission, and 404 
presenting with lower systolic blood pressure. This sex-specific hypercoagulability did not appear to increase the risk of 405 
thrombotic morbidity and it was not dependent on age. It is conceivable that epigenetic or post-translational processes due 406 
to lifetime exposure to female sex hormones could alter platelet progenitor function or cellular clotting biology, leading to 407 
a persistent hypercoagulable state during menopause.196 The same Denver group197, studying healthy volunteers aged 18-55 408 
years, described that females had shorter time to clot formation, higher rate of clot propagation, and increased clot strength 409 
than males. The study showed higher levels of total and functional fibrinogen in women compared to men, but no difference 410 
in fibrinolysis. Collectively, these findings suggest that more circulating functional fibrinogen and faster coagulation 411 
activation may be involved in women’s resilience to TIC. Other studies have found that men have lower fibrinogen levels 412 
as well as platelet count and function compared to women198. Platelets express receptors for estrogens, which might affect 413 
their function and hemostatic ability199, and testosterone reduces agonist-induced aggregation200. Studies have shown 414 
conflicting results regarding platelet aggregation over the menstrual cycle201,202. The Denver group203 showed that healthy 415 
men’s platelets pre-treated with estradiol approximated the women’s platelet activation response to platelet-activating 416 
factor, suggesting that donor sex should be considered in transfused platelets, and encouraging investigation of estradiol’s 417 
therapeutic potential in TIC. Timing is also a potential factor, as serial viscoelastic tests suggest that women convert to a 418 
hypercoagulable profile postinjury earlier than their male counterparts204.  419 
Current postinjury resuscitation protocols are not sex-specific, theoretically exposing women to unnecessary transfusions. 420 
Given the low representation of women in trauma cohorts, a type 2 error cannot be excluded as an explanation for the lack 421 
of sex differences in transfusion requirements185,205. Carefully sized, inevitably large, RCTs testing sex-specific thresholds 422 
for hemostatic resuscitation, considering menstrual cycle, pregnancy and menopause, will ultimately be required.  423 
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[H1] Diagnosis, Screening and Prevention    424 
 Clinical trials have demonstrated challenges in identifying patient at risk of major bleeding, and thus clinically relevant 425 
TIC. First, there is controversy over the definition of massive transfusion. Early definitions of massive transfusion included 426 
the military description of 10 units of red blood cells (RBCs) in a 24-hour period206. These definitions have matured to focus 427 
on shorter intervals as detailed in the glossary207-209. The shorter timeframe is driven by the fact that the median time to 428 
death from bleeding is <3 hours6,9,51, and that longer time frames lead to survivor bias (i.e., patients may die of hemorrhage 429 
early, before having the “opportunity” to receive more blood). Second, although a number of scores have been proposed, 430 
the positive predictive value remains low. Consequently, the lack of scoring systems with good predictive performance 431 
present major challenges to forecasting those who will develop TIC. As an example of the challenges faced in TIC prediction 432 
and consequently in designing clinical studies, in the large CRASH-2 international trial of tranexamic acid (TXA) for 433 
traumatic hemorrhage210, with over 20,000 patients, only half of the patients received a blood transfusion despite being 434 
clinically assessed to be at risk for major bleeding.  435 
Fortunately, massive transfusion rates for patients meeting trauma team activation are infrequent (3%-17%), however, 436 
massively bleeding patients are at great risk for TIC.211-213 Identification of TIC within a cohort of massively bleeding 437 
patients can be augmented by laboratory testing. The conventional tests include a platelet count, Clauss fibrinogen level, 438 
prothrombin time (PT), and activated partial thromboplastin time (aPTT), (Box 1). A major limiting factor with these 439 
assays is the time to results for multiple tests, and inability to identify hyperfibrinolysis. The alternative currently is 440 
viscoelastic haemostatic assays (VHA) in a single read-out. Conventional coagulation assays can take up to 40 minutes 441 
before actionable data are available, whereas VHA provide real time data with results that can come back in half the time 442 
211. Some newer interpretive modifications on VHA have actionable results in 5 minutes, identifying patients at risk of 443 
massive bleeding166,214. Additionally, a clinical scoring system for assessing TIC, which includes subclassifications for 444 
anatomic location of injury and interventions required for bleeding control, has been proposed (Box 1) 215. This scoring 445 
system correlates well with laboratory detected coagulopathy and blood transfusions but requires assessment in the OR165. 446 
The rapid availability and comprehensive information of VHA has led to recommendation that VHA (Figure 10) should 447 
replace conventional coagulation testing in TIC assessment7. VHA use to guide resuscitation in trauma has been associated 448 
with reduced mortality in a randomized trial14. The recent ITACTIC study216 reported no differences in clinical outcomes 449 
of VHA versus conventional coagulation guided resuscitation. However, their VHA resuscitation thresholds were not based 450 
on outcomes, rather they were based on the conventional testing used in the control group, thereby creating a circular logic 451 
that resulted in the two groups being treated similarly. The conclusion from the ITACTIC study is that resuscitation based 452 
on those specific VHA thresholds did not offer benefit over conventional tests guidance, but does not offer evidence for 453 
different, outcome-based VHA resuscitation thresholds. Although the evidence in trauma is limited, substantial evidence 454 
from elective cardiac and liver transplant surgery studies provide further support for use of VHA217. 455 
TIC has been historically defined by PT or international normalized ratio (INR), (Box 1) with prolongation detected in 456 
one in four severely injured patients meeting high level of trauma team activation82,83. Mortality in this cohort can be up to 457 
four fold higher than in similarly injured patients without prolonged PT, and the need for blood product resuscitation is 458 
significantly higher82. Thus, prolonged PT/INR or aPTT were proposed as clinical tests to identify TIC. However, a number 459 
of studies have subsequently documented that PT/INR may be abnormal postinjury despite normal clotting factor activity 460 
levels205,218. Furthermore, the exact conventional coagulation assay based definition of TIC remains a topic of debate as 461 
some investigators argue the threshold is an INR>1.283, while others claim it should an INR>1.582. PT/INR only reflects the 462 
contribution of plasma proteins to clot formation and specifically ignores the central role of platelets. Consequently, VHAs 463 
have been adopted for the diagnosis of TIC in many countries219-222, due to the assessment of whole blood clot formation 464 
and degradation in real time, although there has been criticism of assay reproducibility in older versions of VHA devices 465 
and its ability in measuring hyperfibrinolysis296. Viscoelastic evidence of decreased clot strength has repeatedly been 466 
associated with massive transfusion and increased mortality in trauma223-225, although there is discordance on specific 467 
thresholds defining hyperfibrinolysis. Indeed, Vigneshwar et al. showed that such cutoffs should not be fixed, but combined 468 
with clinical signs of injury severity and shock.226 469 
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Given the vast array of coagulation changes in trauma patients, defining TIC with a single laboratory measurement is 470 
imprecise. TIC is a complex process that involves the endothelium, platelets, circulating coagulation factors, and the 471 
immune system21,227, and no single assay or set of assays available to date effectively integrate measurement of the critical 472 
coordinated events involved in vascular homeostasis. Ex vivo laboratory assays to assess coagulation fail to account for 473 
theese important factors and are subject to limitation such as the use of buffers for collection that neutralize acidosis. 474 
Viscoelastic identified hyperfibrinolytic phenotypes are frequently associated with early mortality rates exceeding 475 
50%9,153,158, while fibrinolysis shutdown is associated with delayed mortality160 Importantly, the findings of coagulation 476 
testing are similar in both pediatric patients and adults, with principal component analysis detecting similar phenotypes of 477 
TIC, and VHA predicting outcomes in a similar manner in children228 as in adults.  Even in the setting of an abnormal 478 
laboratory test, the clinical status of the patient ultimately drives decision making. Abnormal laboratory results need not be 479 
corrected with blood products in a patient with no clinical signs of coagulopathy and surgical/interventional hemostasis. 480 
TIC becomes vastly more complex following resuscitation. The prior sections have focused on early TIC, which is mostly 481 
an innate coagulation response to tissue injury and hemorrhagic shock. However, with resuscitation, fluid administration, 482 
blood products, and hemostatic agents result in potential secondary coagulopathies as well as hemodilution, acidosis, and 483 
hypothermia21. Further, in the event of uncontrolled bleeding due to lack of mechanical control, this coagulopathy is 484 
exacerbated. Following resolution of hemorrhage and hypoperfusion, most patients transition from an early hypocoagulable 485 
to a late hypercoagulable state229. Late hypercoagulable TIC presents a new set of challenges in clinical management focused 486 
on prevention of thrombotic complications21. The specific laboratory definition of late hypercoagulable TIC remains even 487 
more elusive, but several studies have identified increased clot strength and fibrinolysis shutdown, as measured by VHA, 488 
following resuscitation as a risk factor for venous thromboembolism230-232 and stroke233.  Trending VHA during hospital 489 
admission180 has identified changes in TIC phenotype associated with  thrombotic complications, however, the measures to 490 
mitigate late TIC are presently focused on best practice of hemostatic resuscitation with blood products, and 491 
thromboprophylaxis.   492 
[H1] Management  493 
  494 
[H2] Prehospital care    495 
The initial management of TIC focuses on preventing progression to hemorrhagic shock by arresting the bleeding, and 496 
restoring circulating blood volume, thereby, attenuating the effects of acidosis on coagulation. Efforts have been made to 497 
make the public aware of strategies such as tourniquets (“Stop the Bleed” and “STOP the Bleeding Campaign”)234,235 and 498 
direct compression of bleeding wounds to slow hemorrhage. Prehospital health care providers also initiate resuscitation of 499 
the critically ill trauma patient with to increase intravascular volume to preserve organ perfusion. The fluids administered 500 
in the prehospital setting to increase the effective circulating volume can help but potentially harm the patient. Large volume 501 
crystalloid resuscitation can increase the blood pressure, but may also exacerbate coagulopathy and “pop the clot”236 if blood 502 
pressure is raised too rapidly. Permissive hypotension with low volume crystalloid administration has been demonstrated to 503 
be effective for the management of trauma patients in the prehospital setting237. High volumes of crystalloid resuscitation 504 
have been associated with hyperfibrinolysis upon presentation to the hospital158 partially through dilution of antifibrinolytic 505 
circulating proteins238, in addition to being independently associated with morbidity 239. A permissive hypotensive strategy 506 
in actively bleeding patients is advocated in trauma patients until definitive bleeding control can be achieved, but the optimal 507 
level of hypotension remains to be established, particularly with TBI.  508 
Additional adjuncts in the prehospital setting include the transfusion of blood products. Prehospital plasma resuscitation 509 
reduces mortality in patients who undergo helicopter transportation6. However, plasma first resuscitation in an urban setting 510 
with short transportation time did not reduce mortality and was associated with a prolonged INR5. In a post-hoc analysis of 511 
two recent clinical trials of prehospital plasma with harmonized inclusion criteria, the benefit of prehospital plasma appeared 512 
to be limited to those with transport times exceeding 20 minutes240. Ongoing work is evaluating the potential role of 513 
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lyophilized plasma in the prehospital setting, as it overcomes the logistical challenges of de-thawing plasma in the mobile 514 
setting. Efforts are also being made to evaluate the use of whole blood as a prehospital resuscitation strategy, which has 515 
been proven to be feasible241, but impact on coagulopathy remains to be determined 242.  516 
TXA has been shown to reduce mortality in a large trauma study 210, and therefore has been implemented in some prehospital 517 
systems. But the optimal target group remains unclear. Recently, two large randomized clinical trials of prehospital TXA 518 
have been reported. The Study of Tranexamic Acid during Air and ground Medical Prehospital transport (STAAMP) 243 519 
trial was a phase-3, multicenter RCT of TXA versus placebo, given within an estimated 2 hours postinjury in the prehospital 520 
setting to patients with hypotension or tachycardia. The study demonstrated no significant difference in the primary outcome 521 
of 30-day mortality (9.9% placebo, 8.1% TXA, p=0.17). However, in a pre-planned subgroup analyses, patients with severe 522 
shock (systolic blood pressure <70mmHg) who received TXA within one hour postinjury had a statistically significant 523 
reduction in 30-day mortality. Similarly, the Prehospital TXA for TBI Trial 244 was a randomized, double blind, multicenter 524 
phase-2 trial designed to assess safety and efficacy of TXA versus placebo in patients with moderate to severe TBI but 525 
without hemorrhagic shock. This study evaluated TXA given within 2 hours postinjury in the prehospital setting as either a 526 
1g TXA bolus with in-hospital 1g infusion, 2g bolus followed by in-hospital infusion, or placebo with a primary outcome 527 
of favorable neurologic function at 6 months. Neither dosing strategy of TXA was found to be superior, with no statistically 528 
significant difference in the primary outcome nor 28-day mortality when dosing strategies were combined in the analysis. 529 
When assessed independently as a secondary analysis, however, the 2g prehospital bolus was associated with a trend towards 530 
reduced mortality243, although this came at the expense of an increase in the rate of seizures from 2% (placebo) to 6% (2-g 531 
bolus).  However, RCTs on TXA have not randomized patients based on their fibrinolytic status.  532 
The potential risk of VTE with TXA has been a topic of debate. Retrospective studies in both civilian245 and military 533 
medicine246 suggest an association with increased VTE rates, although these studies were limited by their retrospective 534 
design. The use of TXA as an anti-fibrinolytic could theoretically increase the incidence of postinjury fibrinolysis shutdown, 535 
and the observation that late (>3 hours postinjury) TXA is associated with death247 strongly indicates that TXA should be 536 
administered early, and likely not given to patients with evidence of fibrinolysis shutdown248,249  A small single-center 537 
randomized trial in severely injured trauma patients suggested a dose-dependent increase in a composite outcome of 538 
thrombotic events in patients receiving TXA (% of thrombotic events, placebo 12%, 2g TXA 27%, 4g TXA 32%, p=0.05)250. 539 
The recent HALT-IT trial 251 of TXA in gastrointestinal hemorrhage indicated a significant increase in VTE with a 4g dose 540 
of TXA given over 24 hours (placebo 0.4% vs TXA 0.8%, Relative Risk 1.85; 95% CI: 1.15-2.98). In contrast, the CRASH-541 
2210 and CRASH-3252 trials randomized tens of thousands of patients at risk for hemorrhage postinjury to TXA vs placebo, 542 
and neither study demonstrated a VTE increase. This aligns with the observation of safety and low VTE rates in randomized 543 
trials of TXA in other bleeding conditions such as post-partum hemorrhage253. CRASH-2 and CRASH-3 have been criticized 544 
for reporting VTE rates substantially lower than most studies, possibly due to the low rate of patients who actually required 545 
transfusion. However, the STAAMP and Prehospital TXA for TBI trials had substantially higher VTE rates than those 546 
reported in the CRASH studies.254  547 
[H2] Hospital care   548 
Patients who arrive to the hospital in overt hemorrhagic shock warrant empiric blood product resuscitation to restore 549 
circulating blood volume and thereby attenuate the development of worsening coagulopathy. This includes a high ratio of 550 
plasma to RBCs to attenuate exacerbation of coagulopathy206. The exact ratio of RBCs to plasma remains debated but should 551 
be at minimum 2:1. The only RCT evaluating these ratios demonstrated no benefit in survival with 1:1 over 2:142, but 552 
suggested a shorter time to hemostasis in the higher ratio group. This study also included early platelet transfusions in the 553 
1:1 arm, which has been associated with improved outcomes in trauma in a retrospective study255. These improved outcomes 554 
with high ratios of these products are limited to trauma patients undergoing a massive transfusion, and there is evidence that 555 
the non-massively transfused trauma patients may be harmed by using these blood products. High ratios of 556 
fibrinogen/cryoprecipitate (Box 1) to RBC have also been advocated to decrease trauma mortality256, but await the results 557 
of ongoing RCTs. The new proposal (but historic practice) to high ratio resuscitation is the use of whole blood257. Low anti-558 
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A and anti-B titer, group 0 whole blood (LTOWB) was the standard for trauma resuscitation until blood component 559 
separation in the early 1980s, and has been shown to be feasible and safe as initial fluid in the United States258,259. In a single 560 
center study of injured adults, the use of LTOWB has been associated with reduced transfusion volumes and increased in 561 
survival compared to component therapy260. The safety of LTOWB has been confirmed also for pediatric patients presenting 562 
with hemorrhagic shock. If empiric ratios of RBC and plasma are used to resuscitate massively bleeding patients, 563 
cryoprecipitate/fibrinogen and platelets should be initiated if the patient has begun to receive more than four units of RBCs 564 
before laboratory results are available209.   565 
Bicarbonate should be given only if severe acidosis persists despite resuscitation, as bicarbonate therapy has been shown to 566 
be ineffective or harmful in general. Its harm is due to excess HCO3-derived CO2, which is very soluble across cell 567 
membranes, causing a cellular respiratory acidosis not reflected in arterial pH or PaCO2 measurements261,262.  568 
All trauma patients with major bleeding need ongoing coagulation assessment regardless of their transfusion strategy, as 569 
demonstrated in a RCT of goal directed resuscitation, guided by VHA, in which mortality was reduced by almost 50% in 570 
trauma patients in whom a massive transfusion protocol was activated14. Goal directed resuscitation targets the patient’s 571 
specific coagulation phenotype, with the objective of achieving a normal coagulation profile without excessive blood 572 
component use, which has been associated with the best outcome263. Algorithms for specific hemostatic adjuncts including 573 
plasma, cryoprecipitate/fibrinogen, platelets, and TXA can be directed with VHA or equivalent hemostatic assays 264-574 
266(Figure 11).  A recent meta-analysis of VHA supports this concept as pooled randomized control data in patients 575 
undergoing VHA-based emergency resuscitation consumed less plasma and platelets with an associated reduction in post-576 
operative mechanical ventilation days217. However, a reliable test to ascertain when to administer platelets in trauma patients 577 
is lacking.  Impairment in platelet-dependent hemostasis characteristic of TIC do not predict the need for platelet transfusion, 578 
nor do platelet transfusions reverse these impairments122,123,267.  Ultimately, the clinical status of the patient should  579 
While no specific studies have evaluated the timing of coagulation assessment in trauma, the dynamic nature of resuscitation 580 
warrant early and repeated monitoring until hemostasis is achieved and a return to balanced resuscitation is warranted if 581 
hemostasis is lost.  582 
Trauma patients who present to the hospital with occult bleeding but who are physiologically compensated pose a different 583 
challenge in resuscitation. A common source for occult bleeding is solid abdominal organ injury, which can be managed 584 
predominantly with non-operative interventions. Targeted resuscitation of these patients is an important approach as most 585 
transition to a hypercoagulable state by 24-48 hours.230,231 .  586 
TBI poses unique challenges in management of coagulation. Unlike abdominal and thoracic cavities that can accommodate 587 
moderate amounts of bleeding, the fixed space in the calvarium warrants a more aggressive approach in obtaining timely 588 
hemostasis. The CRASH-3 study identified a survival benefit in early TXA in mild to moderate TBI, but no benefit in severe 589 
head injury 268. The protective effect of TXA in TBI, however, remains unclear and may be more related to countering 590 
inflammation than improving hemostasis. TBI represents a unique phenotype of TIC, however the resuscitation and 591 
management of TBI associated TIC are largely similar to coagulopathy associated with non-TBI injury. One major challenge 592 
in TBI associated TIC is the use of pharmacologic prophylaxis against VTE. The transition to hypercoagulability after injury 593 
poses a major clinical challenge, with high VTE rates noted in patients who have TBI. The decision to initiate 594 
anticoagulation to prevent postinjury clotting and thrombotic complication needs to be weighed against the risk of 595 
exacerbating bleeding, particularly with associated brain injury. Early VTE prophylaxis in TBI patients has been associated 596 
with a reduction in VTE incidence without worsening of intracranial hemorrhage when started after a stable head CT269. 597 
Low-molecular weight heparin has been shown to be superior to unfractionated heparin in this cohort, with improved 598 
survival and fewer thromboembolic complications270. Due to patient immobility and the hypercoagulable state, 599 
thromboprophylaxis is administered as soon as possible after bleeding risk has subsided and individual patient factors must 600 
guide the choice of UFH or LMWH271,272. 601 
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Importantly, global variations exist with respect to resuscitation strategies (Box 3). As an example, the European 602 
guidelines157 on the management of major bleeding and coagulopathy following trauma strongly emphasize that early 603 
resuscitation with cryoprecipitate or fibrinogen concentrate to overcome rapid depletion of fibrinogen in trauma patients.  604 
This varies from a largely “plasma first” and platelets approach to hemostatic resuscitation in the United States.  Further 605 
complicating this issue is the lack of stored blood and its components in many parts of the developing world, making global 606 
recommendations for management impractical. 607 
 [H1] Quality of Life   608 
 609 
Data from the World Health Organization Global Burden of Disease and Injury study show that, despite sizeable gains since 610 
the 1990’s, injury remains a substantial cause of morbidity around the world273. Few studies provide information on the 611 
long-term outcomes of TIC’s hypocoagulable phenotype. The Trauma Recovery Project (TRP) is a large prospective study 612 
of injured patients without serious head injury that assesses QOL as well as functional and psychological (depression; 613 
posttraumatic stress disorder, PTSD) outcomes.274,275 Adults showed over 75% prevalence of postinjury functional limitation 614 
at 12- and 18-month follow-up. Depression was present in 60% of the patients at discharge and 31% at 6-month follow-up. 615 
In TRP subsequent studies, women were more likely than men to have poor QOL at 6-, 12- and 18-month follow-up274,276. 616 
The TRP in Adolescents 1999-2002 study277, which focused on injured adolescents without serious brain trauma, showed 617 
acute stress disorder (ASD) was present in 40% upon discharge and was associated with large QOL deficits at 3-, 6-, 12- 618 
and 24-month follow-ups. Long-term PTSD’s rate was 27%278. Winthrop et al.279 in a longitudinal study of 156 children 619 
with blunt trauma (but no head/ spinal cord injuries) showed that at 6 months, the physical scores remained lower than age-620 
matched norms.  621 
In the CONTROL international RCT of activated Factor VII,280 including severely injured adults with refractory bleeding 622 
but no severe brain injuries, survivors reported very poor QOL three months postinjury, with over 70% reporting 623 
moderate/extreme difficulties in usual activities, pain/discomfort and mobility limitations. Over half of the patients reported 624 
self-care problems and anxiety/depression. Mitra et al. 281 in an Australian trauma center assessed Glasgow Outcome Score-625 
Extended (GOSE)1 (Box 1) at 6 and 12 months, in adults who required massive blood transfusion postinjury (patients with 626 
TBIs were not excluded) and demonstrated that massive transfusion was independently associated with unfavorable 627 
outcomes among survivors at 6 months postinjury.  628 
The hypercoagulable extreme of TIC, prevalent in patients who survive the initial resuscitation, is linked to MOF and ARDS, 629 
as well as macro-thrombotic complications such as VTE9,165, all associated with prolonged hospitalization. Patients requiring 630 
prolonged intensive care develop a state of chronic critical illness (CCI, defined as ≥ 14 ICU days with persistent organ 631 
dysfunction)282,283, which is associated with dismal long-term outcomes in series of non-TBI trauma patients282,284. Gardner 632 
et al.284, studying non-TBI subjects, showed that CCI subjects at 3-, 6- and 12-month follow-up had significantly lower 633 
physical function and QOL than their counterparts who rapidly recovered. Mira et al.282 followed 135 adult blunt trauma 634 
patients with hemorrhagic shock who survived beyond 48-hours postinjury, of whom 19% developed CCI; these patients 635 
were more likely to require long-term care and, at 4-month follow-up, scored lower in general health measures. 636 
VTE’s incidence postinjury depends on whether there is routine surveillance (versus symptom-driven diagnosis) and the 637 
use of thromboprophylaxis. A comparison of two US trauma centers showed that serial VTE surveillance via ultrasound 638 
detected deep venous thrombosis (DVT) in 9% of patients admitted for > 48 hours, while surveillance of only symptomatic 639 
patients showed a smaller, 2% DVT incidence, despite similar thromboprophylaxis protocols285. Pulmonary embolism (PE) 640 






Trauma Data Bank showed in-hospital VTE rates around 1%192,287,288. In a Switzerland trauma center, VTE’s rate was 7%-642 
10%289, while in Germany, it was reported to be 2%. Military data suggest a higher VTE incidence than in civilians (2 to 643 
22%)290-292. A review of long-term functional outcomes after an acute PE showed that more than half of the patients reported 644 
dyspnea and poor physical performance293 with rates of chronic thromboembolic pulmonary hypertension as high as 3.8% 645 
at two years294. The incidence of post-thrombotic syndrome, a chronic debilitating consequence of acute DVT, has been 646 
estimated to be 20-50% even when appropriately treated295.  647 
[H1] Outlook    648 
 649 
The investigation of the fundamental mechanisms of TIC has been pursued for over a 100 years, beginning with the work 650 
of Walter B. Cannon in World War I296. While there have been substantial insights, Mario Stefanini’s words in his address 651 
to the New York Academy of Medicine in 1954 remain applicable: “The ponderous literature on the subject of hemostasis 652 
could perhaps be considered a classical example of the infinite ability of the human mind for abstract speculation. For 653 
several years, the number of working theories of the hemostatic mechanisms greatly exceeded and not always respected the 654 
confirmed experimental facts. In recent years, however, the revived interest in this field has led to an accumulation of new 655 
findings, which has been almost too rapid for their orderly incorporation into a logical working pattern” 297. While 656 
Stefanini’s words apply to today, we have made substantial progress over the past three decades stimulated by the 657 
introduction of the cell-based model of hemostasis, and further inspired by the confirmation that uncontrolled cavitary 658 
bleeding was the leading cause of death in the War in Iraq3. Despite much knowledge gained, there are a myriad of gaps to 659 
be addressed. 660 
Perhaps most conspicuous is a clinical definition of TIC, and further distinguishing between the dynamic 661 
early/hypocoagulable versus late/hypercoagulable based on a mechanistic foundation. The initial proposal of using PT/INR 662 
to define early TIC has been subsequently questioned, and rather considered a biomarker of injury. Clinical coagulation 663 
scoring systems have been developed, but these are relatively insensitive unless based on cavitary exposure in the operating 664 
room. Definitions of massive transfusion, e.g., > 4 RBC units or death from bleeding in the first hour postinjury has been 665 
suggested but does not capture the impact of TIC on TBI. Additionally, multiple TIC phenotypes exist, and these need to 666 
be defined to optimize goal-directed therapy. As a corollary, of those patients with refractory early TIC, how do we 667 
distinguish between those patients who are “dying because they are bleeding” from those “bleeding because they are dying?” 668 
A number of mechanistic hypothesis have been proposed to drive early TIC, but definitive evidence remains elusive for 669 
many. Notably among the controversial proposals are the roles of thrombin-induced activation of protein C and heparan 670 
sulfate released from the disrupted endothelial glycocalyx. Shock and tissue ischemia appear to dominate in early TIC, but 671 
the mediators remain to be identified, including metabolites. The contributing role of tissue injury is also unclear, and may 672 
be critical in determining early fibrinolytic phenotypes. Interestingly, isolated shock or TBI are not associated with a 673 
pronounced TIC but, in combination with tissue injury, provoke a conspicuous early TIC. In fact, the mechanisms driving 674 
TIC from TBI appear to be unique and need to be elucidated. There is clear evidence of cross-talk between inflammation 675 
and coagulation but the direct links remain to be elucidated. 676 
Early TIC has been suggested to result from a combination of inadequate thrombin generation, platelet dysfunction, 677 
fibrinogen depletion, and hyperfibrinolysis. However, the relative contribution of these abnormalities remains unclear, and 678 
some of these coagulation aberrations may be biomarkers rather than critical mechanistic drivers. While thrombin generation 679 
has been described as accelerated following trauma, recent evidence indicates it is depressed in patients requiring a massive 680 
transfusion22. On the other hand, excessive thrombin generation has been associated with VTE. What constitutes appropriate 681 
thrombin in the evolution of TIC is unknown. Platelet dysfunction has been well documented following severe injury, but 682 
its etiology, mechanism, and role in early and late TIC remain unclear. The findings of dysfunction in circulating platelets 683 
may represent the platelets that have already functioned, rather than the hemostatic capacity of the platelet reserves in the 684 
local injury environment. Fibrinogen is the first circulating coagulation protein decreased following severe injury, but what 685 
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critical level warrants replacement remains to be established. The overlapping roles of platelets and fibrinogen in clot 686 
formation compounds the issue; i.e., one of these components may compensate for a deficiency in the other. Finally, the 687 
impact of fibrinolysis phenotypes in early and late TIC remains debated. While hyperfibrinolysis may compromise 688 
hemostasis, shutdown may contribute to later ARDS and MOF. These observations continue to raise the question of whether 689 
TXA should be used selectively following injury, particularly in the USA. 690 
The endothelium is the “black box” in TIC. Endothelial activation has been invoked as a dominant feature of early TIC, but 691 
this is based on the presence of shed biomarkers, rather than real-time assessment of endothelial behavior. The 692 
endotheliopathy of trauma, and more specifically barrier breakdown, has been documented in vitro and in vivo but the 693 
relationship to TIC remains speculative.  694 
The optimal coagulation platform to assess early and late TIC has yet to be developed. The shortcomings of traditional 695 
plasma-based tests (PT/INR, aPTT) have been recognized, and they have been replaced by viscoelastic hemostatic assays 696 
(TEG and ROTEM). Although TEG and ROTEM whole blood assays reflect the various phases of clot formation, they are 697 
not performed on activated endothelium with physiologic shear stress. Furthermore, these devices are not reliable to 698 
ascertain platelet functional capability and their precision in measuring fibrinolysis is debated298. Microfluidic devices have 699 
been employed for research and will likely emerge for clinical use soon. Consequently, at this time, we are unable to 700 
accurately determine the timing and specific blood products required to avert a massive transfusion or progressive TBI. We 701 
are currently unable to clearly discern the transition from hypocoagulability to hypercoagulability, and this state may differ 702 
in the arterial (high shear stress) versus venous (low shear) systems. Consequently, we continue to debate when to initiate 703 
VTE preventive therapy and the optimal preventive agents.  704 
Ultimately, the goal of personalized medicine of the injured patient at risk for TIC is to deliver the right product(s) at the 705 
right time to the right patient. However, our current understanding of the pathophysiology of TIC remains incomplete despite 706 
intense research focus, and compounded by limitations in diagnostic testing, rendering current clinical decisions imprecise. 707 
For example, there are disparate views across the Atlantic as to whether early platelets or fibrinogen are optimal. Additional 708 
questions include whether cryoprecipitate is superior to fibrinogen concentrates, whether PCCs are equivalent to FFP, and 709 
whether TXA should be administered selectively to trauma patients based on injury pattern. While initial administration of 710 
low-titer type O-positive whole blood (LTOWB) is attractive, returning to stored whole blood throughout resuscitation is 711 
not consistent with our knowledge of the varied phenotypes of TIC. 712 
Figure Legends 713 
• Figure 1: Phenotypes of Trauma Induced Coagulopathy 714 
Physiologic clot formation and degradation represent a delicate balance of prothrombotic/antithrombotic and 715 
fibrinolytic/antifibrinolytic processes. Consequently, there are distinct early and late phenotypes resulting from tissue 716 
injury, shock, traumatic brain injury (TBI) as well as individual response to these insults. Adapted from From Moore 717 
EE, Moore HB, Chapman MP, Gonzalez E, Sauaia A. Goal-directed hemostatic resuscitation for trauma induced 718 
coagulopathy: Maintaining homeostasis. The Journal of Trauma and Acute Care Surgery. 2018 Jun;84(6S Suppl 1):S35-719 
S40. DOI: 10.1097/ta.0000000000001797. 720 
 721 
• Figure 2: Mechanisms of Trauma Induced Coagulopathy 722 
Progress in understanding the pathogenesis of TIC has been inspired by the revolutionary concept of the cell-based 723 
model of coagulation that emphasizes the fundamental role of platelets as a platform for clotting factor assembly, 724 
thrombin generation and incorporation of fibrin to form a hemostatic plug on damaged endothelium. While there are a 725 
number of hypotheses for the driving mechanisms, tissue injury and shock synergistically activate the endothelium, 726 
platelets and the immune system to generate an array of mediators that reduce fibrinogen, impair platelets function, and 727 
compromise thrombin generation ultimately resulting in inadequate clot formation for hemostasis. Enhanced 728 
fibrinolysis via plasmin generation further compromises hemostatic capacity. These defects are accentuated by ongoing 729 
blood loss, hemodilution, metabolic acidosis, and hypothermia (the lethal triad).  730 
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  731 
• Figure 3: Distribution of All Hemorrhagic Deaths Over Time in Three Randomized Controlled Trials  732 
o PROPPR 4,42(n = 680) Time zero= randomization in-hospital; Entry criteria: > 1 unit of blood product and 733 
Assessment of Blood Consumption score>1 or physician’s prediction of massive transfusion need  734 
o PAMPer (n = 501)6 Time zero=scene arrival; Entry criteria: Air transported and Systolic Blood Pressure 735 
(SBP)<70mmHg or SBP <90mmHg + Heart Rate (HR)>108bpm  736 
o COMBAT (n = 144) 5Time zero=dispatch; Entry criteria: Ground transported and SBP<70mmHg or SBP 737 
<90mmHg + HR>108bpm  738 
o Note: Among patients requiring > 1 unit of red blood cells/24 hours, 85% of the hemorrhagic deaths in PAMPer 739 
and 50% in COMBAT occurred <6 hours. 740 
Adapted from Sauaia A, Moore EE, Wade C, Holcomb JB. Epidemiology of Hemorrhagic Deaths. In: Moore HB, Neal 741 
MD, Moore EE, eds. Trauma Induced Coagulopathy. 2nd. ed.: Springer; 2020 742 
 743 
• Figure 4: Platelet and Endothelial Interactions 744 
In health, endothelial cell architecture projects beyond cell membranes via a glycocalyx of polysaccharides linked to 745 
membrane and trans-membrane proteoglycans (protein cores attached to glycosaminoglycans), fortified with soluble 746 
glycoproteins that coordinate coagulation and immune functions. The glycocalyx provides cytoprotection, membrane 747 
integrity, and anti-apoptotic anti-thrombotic signaling. Extracellular proteases, like metalloproteases (MMPs), cleave 748 
glycocalyx ectodomains, and expose neutrophil adhesion receptors for neutrophil binding and chemo-attractant and 749 
cytokine release.  Clot formation relies on platelet plug construction (primary hemostasis) by thrombin-stimulated 750 
platelet adherence to exposed extravascular matrices via tissue factor (TF), von-Willebrand Factor (vWF), collagen, 751 
and protein structure. Thrombin-stimulation and platelet glycoprotein VI-collagen binding induce calcium mobilization, 752 
disc to sphere structure, procoagulant factor degranulation, and glycoprotein IIb/IIIa receptor conformational change to 753 
accept fibrin binding. Additionally, platelets control local fibrinolysis via degranulation of plasminogen activator 754 
inhibitor-1 (PAI-1) and antiplasmin-2 rich alpha-granules to maintain prothrombotic, antifibrinolytic clot architecture. 755 
Secondarily, activated platelets recruit leukocytes to local environments. Further, via reciprocal trophogenesis, platelets 756 
promote endothelial stability and angiogenesis in return for endothelial release of factors promoting platelet-dependent 757 
hemostasis like vWF, and of cytokines signaling megakaryocytes to produce platelets.  758 
 759 
• Figure 5:  Cell-Based Model of Coagulation  760 
Initiation occurs on TF-bearing cells as the FVIIa/TF complex activates FX. Fxa binds to its cofactor, Fva, and activates 761 
small amounts of thrombin. Thrombin generated on the TF-bearing cell amplifies the procoagulant response by 762 
activating additional coagulation factors and platelets. The large burst of thrombin required for formation of a fibrin 763 
clot is generated on platelet surfaces during the propagation phase. Adapted from Hoffman M, Monroe DM. Impact of 764 
Non-Vitamin K Antagonist Oral Anticoagulants From a Basic Science Perspective. Arterioscler Thromb Vasc Biol. 765 
2017;37(10):1812-1818. doi:10.1161/ATVBAHA.117.306995 766 
 767 
• Figure 6: Clotting Factor Cascade 768 
Fibrin formation via the proteolytic clotting factor cascade represents a delicate balance of prothrombotic and 769 
antithrombotic mediators. The extrinsic or tissue factor cascade is initiated by binding of TF and Factor VIIa stimulating 770 
the activation of Factor X to complex with Factor Va (prothrombinase), while the intrinsic or contact activation pathway 771 
is provoked by a negatively charged surface, prekallikrein, high-molecular weight kininogen or Factor XII that activate 772 
Factor XI and similarly results in the assembly of prothrombinase complex in the common pathway. The extrinsic and 773 
intrinsic systems are not redundant but rather participate synergistically in thrombin formation. Adapted from Gando, 774 





• Figure 7: Multifunctional Roles of Thrombin 778 
Once activated by the coagulation cascade, thrombin can function in procoagulant, anticoagulant, antifibrinolytic, and 779 
pro/anti-inflammatory pathways. The serin protease thrombin stimulates multiple procoagulant and anticoagulant 780 
(protein C) pathways and inhibits fibrinolysis (TAFI) and is a strong platelet activator (PAR). Moreover, thrombin is 781 
involved in pro- and anti-inflammatory pathways. Adapted from Crawley JT, Zanardelli S, Chion CK, Lane DA. The 782 
central role of thrombin in hemostasis. J Thromb Haemost. 2007 Jul;5 Suppl 1:95-101. doi: 10.1111/j.1538-783 
7836.2007.02500.x. PMID: 17635715.Supp 1) 95-101) 784 
 785 
• Figure 8: Fibrin Formation 786 
Thrombin-catalyzed conversion of soluble fibrinogen to insoluble fibrin matrix is central to hemostasis. Fibrin 787 
polymerization is initiated by cleavage of the fibrinopeptides A and B located in the central E-domain. These 788 
fibrinopepides mask complementary polymerization sites in the gamma-C and beta-C regions of the D-domains. Two  789 
fibrin monomers interact with each other in a half-staggered manner.  790 
 791 
• Figure 9: Regulation of Fibrinolysis 792 
PAI-1 is the primary inhibitor of tPA, its back up inhibitor is C-1 esterase inhibitor. Depletion of multiple inhibitors of 793 
fibrinolysis after fibrinolytic activation in trauma beyond PAI-1 includes a wide range of proteins that can directly bind 794 
PAI-1 (alpha-1 antitrypsin) or modulate its activity (vitronectin). Platelets also provide an abundant source of local PAI-795 
1 with alpha degranulation. Additional regulators of clot degradation including thrombin activated fibrinolysis inhibitor 796 
(TAFI) and factor XIII. Factor XIII plays a critical role in clot stability to fibrinolysis by cross-linking plasmin’s main 797 
inhibitor into growing fibrin polymers. Adapted from Urano T, Suzuki Y. Thrombolytic therapy targeting alpha 2‐798 
antiplasmin. Circulation 2017; 135: 1021–3. 799 
 800 
• Figure 10: Viscoelastic Hemostatic Assays 801 
Thrombelastography (TEG) and rotational thromboelastometry (ROTEM) are currently the most widely used 802 
viscoelastic assays to assess and manage TIC. They have similar measurements to reflect the phases of clot formation 803 
and clot degradation. The respective measurements for TEG and ROTEM are: the reaction (R)-time and clotting time 804 
(CT), time until clot firmness amplitude of 2mm; the coagulation (K)-time and clotting formation time (CFT), time 805 
between 2 and 20 mm clot firmness amplitude; the alpha angle for both, tangent line between baseline and 2 mm point; 806 
maximum amplitude (MA) and maximum clot firmness (MCF), maximum clot firmness achieved; and lysis at 30 min 807 
after MA (LY 30) and residual clot firmness at 30 min after CT (LI 30). Adapted from Harr, J.N., Moore, E.E., Chin, 808 
T.L. et al. Viscoelastic hemostatic fibrinogen assays detect fibrinolysis early. Eur J Trauma Emerg Surg 41, 49–56 809 
(2015) 810 
 811 
• Figure 11: Examples of Goal-Directed Algorithm For Hemostatic Resuscitation.  812 
These algorithms are examples of TEG or ROTEM based approaches: 11a. North American example; 11b. European 813 
example (adapted from  Görlinger et al.  Reduction of Fresh Frozen Plasma Requirements by Perioperative Point-of-814 
Care Coagulation Management with Early Calculated Goal-Directed Therapy. Transfus Med Hemother. 2012 815 
Apr;39(2):104-113. doi: 10.1159/000337186. Epub 2012 Mar 8. PMID: 22670128)  816 
 817 
Box 1. GLOSSARY  818 
1. Activated Partial Thromboplastin Time (PTT): PTT is a conventional coagulation assay that measures the 819 
clotting activity of the intrinsic pathway cascade. It tests the function of all clotting factors except factor VII 820 
(tissue factor) and factor XIII (fibrin stabilizing factor). It is often used to monitor patients’ response to 821 
unfractionated heparin infusion, to target therapeutic anticoagulation. 822 
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2. Auto-dilution: shifts of interstitial fluid into the vascular compartment in response to hemorrhagic shock, which 823 
may impair hemostatic capacity. 824 
3. Bleeding-control bundle-of-care: accurate identification of the bleeding patient; damage control resuscitation; 825 
hemostatic techniques with tourniquets, pelvic binders, hemostatic dressings; resuscitative endovascular balloon 826 
occlusion of the aorta; thrombelastography coagulation monitoring; tranexamic acid for significant 827 
hyperfibrinolysis; decreased time to operating room and interventional radiology; goal-directed resuscitation with 828 
blood products. 829 
4. Cryoprecipitate: plasma-derived blood product for transfusion that contains fibrinogen (factor I), factor VIII, 830 
factor XIII, von Willebrand factor, and fibronectin. 831 
5. Damage control resuscitation (DCR): DCR consists of limited crystalloid fluid, permissive hypotension and 832 
administration of balanced blood components in severely injured patients to attenuate TIC. 833 
6. Damage control surgery (DCS): DCS is completing essential operative maneuvers; i.e., control of mechanical 834 
bleeding, shunting critical arteries, controlling gastrointestinal spillage, and packing bleeding sites in patients 835 
manifesting TIC due to ongoing shock, and returning to the operating room to complete definitive reconstruction 836 
after patient stabilizes. 837 
7. Glasgow Outcome Score-Extended (GOSE): global scale for functional outcome that rates patient status into 838 
eight categories (death, vegetative state, lower severe disability, upper severe disability, lower moderate disability, 839 
upper moderate disability, lower good recovery, upper good recovery 840 
8. Goal-directed resuscitation: hemostatic resuscitation with blood components guided by viscoelastic hemostatic 841 
tests directed at normalizing coagulation. 842 
9. Massive transfusion: several definitions exist. The most frequently used is >10 red blood cell (RBC) units/24 843 
hours, although this definition is subject to substantial survivor bias (i.e., persons who died before 24 hours may 844 
not have the “opportunity” to receive 10 units). Other definitions include: 1) the critical administration threshold 845 
(CAT: ≥3 RBC units/hour in the first hour or in any of the first 4 hours from arrival), 2) > 4 RBC units or death in 846 
the first hour postinjury, which has the advantage of minimizing survivor bias; and 3) > 4 RBC units within the 847 
first hour, is also known as the resuscitation intensity (RI) definition. 848 
10. Potentially preventable trauma deaths: (1) the injury must be survivable, (2) the delivery of care is suboptimal, 849 
and (3) the error in care must be directly or indirectly implicated in the death of the patient. 850 
11. Primary and secondary hemostasis: Primary hemostasis refers to platelet aggregation plug formation on an 851 
injury site, while secondary hemostasis refers to the deposition of insoluble fibrin, generated by the proteolytic 852 
coagulation cascade, into the platelet plug, which forms a mesh that is incorporated into and around the platelet 853 
plug. 854 
12. Prothrombin time (PT) and International Normalized Ratio (INR): PT is a conventional coagulation assay 855 
that evaluates the extrinsic and the common pathways of the coagulation cascade. The PT result (in seconds) on a 856 
normal individual varies between different types and batches of manufacturer's tissue factor used. The INR was 857 
devised to standardize the results. Manufacturers assign an International Sensitivity Index (IST) for their tissue 858 
factor and the INR is calculated as (PT test/ PT normal) IST 859 
13. Viscoelastic hemostatic assays: assays based on the whole blood; measure change in viscoelastic properties of 860 
the whole blood during clot formation, strength and dissolution. The most commonly used devices are 861 
thrombelastography (TEG) and rotational thromboelastometry (ROTEM). 862 
 863 
  864 
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Box 2:  Critical Appraisal of Trauma-induced Coagulopathy  865 
A critical appraisal of the TIC literature is essential before applying the findings to other patients or research agendas. The 866 
PICOTS (Population/Patients, Intervention, Comparator, Outcome, Time, Setting/System) framework is a useful start:  867 
1) Population: the population studied often varies; massive transfusion is a frequent criterion for inclusion, yet it is defined 868 
variably, which hampers comparisons across studies, and it is subject to survivor bias. Traumatic brain injury (TBI) has 869 
substantial confounding and/or modifying effects on risk factors and outcomes of TIC.  870 
 871 
2) Intervention: it is absolutely critical that authors report (and readers pay attention to) when therapy started related to 872 
the injury, arrival of rescue, hospital admission, initiation of transfusions, bleeding mechanical control, as well as other 873 
events that modify TIC’s risk and/or outcomes.  874 
 875 
3) Comparator: in observational studies, obtaining comparable study groups (for example, by adjustment for confounders 876 
though multivariate or propensity score matching) is a challenge. In hemorrhagic shock, minutes of difference between 877 
the study groups can be of significance. 878 
 879 
4) Outcomes: the definition of TIC varies, with contemporary studies often relying on viscoelastic tests, which, often have 880 
inconsistent cutoffs to define abnormalities. Such cutoffs should not be fixed, but combined with clinical signs of injury 881 
severity and shock.226 882 
 883 
5) Time: the timing when TIC is measured (prehospital, upon hospital admission, before or after transfusions and 884 
hemorrhage control, during ICU admission) is critical for an accurate interpretation. 885 
 886 
6) Setting: thus urban trauma systems with short transport times may experience different rates of TIC than less organized 887 
systems, austere environments or settings with long transport times (e.g., rural areas, air-transported patients). Indeed, 888 
in the COMBAT5 and PAMPer6 randomized controlled trials, patients with transport times longer than 20 minutes were 889 
more likely to experience benefit from prehospital plasma240.  890 
 891 
  892 
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Box 3: Variations in TIC diagnosis and management  893 
 Approach A (favored in North America) Approach B (favored in Western Europe) 
Restoring lost volume Balanced blood components 
Balanced crystalloid solutions with 
vasopressors if needed 
Goal directed 
resuscitation 
Yes, with VHA 
Yes, with either conventional or VHA 
coagulation tests 
Plasma vs Fibrinogen 
Plasma used for volume expansion; 
Cryoprecipitate used to increase fibrinogen 
Fibrinogen used to correct factor deficiency 
Balanced blood 
components 
Typically RBC:Plasma: Platelets 1:1:1 or 
Plasma:RBC 1:2 used to initiate 
resuscitation 
Plasma:RBC ratio of at least 1:2; Platelets 
and PCC based on laboratory testing 
Low titer O negative 
whole blood 
Considered instead of RBC:Plasma: 




Long transport, austere environments Recommended 
VHA: viscoelastic hemostatic assays; RBC: red blood cells; PCC: prothrombin complex concentrate (Factors II, VII, IX, 894 





Supplementary information 898 
• Table S1: Civilian studies addressing hemorrhagic death  899 
• Table S2: Epidemiologic studies of trauma-induced coagulopathy (TIC) since 2000 900 
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